PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-controlled, multipleascending dose, double-blind study was performed in patients with secondary-progressive MS. Treatment was given subcutaneously once weekly for 8 weeks, followed by a 4-week open-label treatment period with active drug. The most common adverse event was transient injection site reactions. Non-significant trend for increases in serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial T H 2 immune response in subjects dosed with PI-2301 at 3 and 10 mg. MRI data indicated a non-significant trend for a reduction of lesion numbers in subjects treated with 1 and 3 mg PI-2301.
Introduction
Glatiramer acetate (Copaxone®) is an amino acid copolymer, a mixture of peptides of various length synthesized using four amino acids, Y, E, A, and K, in a defined ratio but in random order (Varkony et al., 2009; Teitelbaum et al., 1971) . Treatment of relapsing remitting MS (RR-MS) with Copaxone requires once daily subcutaneous (SC) administration of a 20 mg dose. Recent efforts using a higher molecular weight fraction of Copaxone, known as Protiramer, have hypothesized that the larger molecular weight peptide species are more immunoreactive than the lower ones, thus allowing for less frequent dosing, i.e., once weekly. However, results of two pilot studies in RR-MS patients have been inconclusive so far (De Stefano et al., 2009 ).
Copaxone's most common side effects are injection site reactions and transient, self-resolving, systemic post-injection reactions such as chest pain, flushing, dyspnea, palpitations, and anxiety (Ziemssen et al., 2001 ). However, Copaxone has not been associated with clinically significant immune suppression or other serious side effects (Boggild, 2009) . Daily SC administration of Copaxone to patients with RR-MS has been shown to significantly decrease relapse rates, slow disability progression, and reduce the number of new gadolinium-enhancing CNS lesions (Dhib-Jalbut, 2003) .
Although the mechanisms underlying amino acid copolymer efficacy in MS are not fully elucidated, down modulation of anti-self immune responses through binding to major histocompatibility complex (MHC) molecules is believed to be a central component (Fridkis-Hareli et al., 1994) as well as T H 1 to T H 2 immune deviation (Miller et al., 1998) . Such mechanisms are fundamentally distinct from mechanisms of other RR-MS therapeutic modalities, such as beta-interferon (e.g., Avonex®, Betaseron®, Rebif®) or alpha-4 integrin inhibitor (Tysabri®) treatments which interfere with cellular migration (Dressel et al., 2007; Prat et al., 2005; Papeix and Lubetzki, 2009) . Patients suffering from RR-MS are at need for a better immunomodulator that is safe and does not require daily injections. With secondary-progressive MS (SP-MS), the therapeutic options are limited as most existing therapies for MS are not efficacious in this subset of MS patients. The only compound approved for SP-MS is mitoxantrone, but it is not commonly used due to its toxicity (Jarius et al., 2003; Comi, 2009; Martinelli et al., 2009) .
PI-2301 is a new immunomodulator in the class of amino acid copolymers. PI-2301 contains four naturally occurring amino acids Y, F, A, and K. It is made of 52-mer peptides manufactured using solid-phase ☆ The authors from Peptimmune Inc., a for-profit organization, are employees and Dr. Gilles Edan is a consultant for Peptimmune Inc. The employees of CIMNA were contracted for services.
